Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:MEDNASDAQ:NATRNYSE:NUSNASDAQ:VERU On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMEDMedifast$11.96-1.6%$14.04$11.88▼$36.29$130.93M1.05230,041 shs65,337 shsNATRNature's Sunshine Products$11.83-0.4%$13.28$10.81▼$19.92$218.48M1.0648,361 shs28,967 shsNUSNu Skin Enterprises$5.49-2.2%$7.24$5.35▼$14.00$272.88M1.1752,201 shs495,684 shsVERUVeru$0.53+1.7%$0.53$0.45▼$1.75$78.61M-0.691.87 million shs410,850 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMEDMedifast-1.86%-7.10%-15.32%-21.97%-62.32%NATRNature's Sunshine Products-1.49%+1.02%-9.66%-16.63%-37.18%NUSNu Skin Enterprises-5.15%-11.04%-31.71%-18.77%-54.09%VERUVeru-0.06%-2.92%+5.89%-37.75%-58.15%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMEDMedifast3.8213 of 5 stars3.01.00.02.03.41.72.5NATRNature's Sunshine Products3.5292 of 5 stars3.75.00.00.03.11.71.3NUSNu Skin Enterprises3.6921 of 5 stars2.03.02.51.43.52.51.3VERUVeru1.9572 of 5 stars3.51.00.00.02.23.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMEDMedifast 2.00Hold$16.5037.96% UpsideNATRNature's Sunshine Products 3.33Buy$19.0060.61% UpsideNUSNu Skin Enterprises 2.00Hold$6.8825.34% UpsideVERUVeru 3.00Buy$4.33711.49% UpsideCurrent Analyst Ratings BreakdownLatest VERU, NUS, NATR, and MED Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/14/2025NATRNature's Sunshine ProductsDA DavidsonSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy2/19/2025MEDMedifastDA DavidsonSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$17.00 ➝ $16.50(Data available from 4/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMEDMedifast$602.46M0.22$2.45 per share4.88$19.21 per share0.62NATRNature's Sunshine Products$454.36M0.48$1.36 per share8.73$8.36 per share1.42NUSNu Skin Enterprises$1.73B0.16$1.59 per share3.44$13.10 per share0.42VERUVeru$16.89M4.63N/AN/A$0.18 per share2.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMEDMedifast$99.42M$0.1866.507.82N/A0.35%10.64%7.57%4/28/2025 (Estimated)NATRNature's Sunshine Products$15.08M$0.4013.43∞N/A3.81%11.08%7.23%5/6/2025 (Estimated)NUSNu Skin Enterprises-$146.59M-$2.95N/A5.08N/A-8.46%5.86%2.62%5/8/2025 (Estimated)VERUVeru-$37.80M-$0.26N/AN/AN/A-223.85%-112.75%-67.54%5/6/2025 (Estimated)Latest VERU, NUS, NATR, and MED EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q2 2025VERUVeru-$0.06N/AN/AN/AN/AN/A5/8/2025Q1 2025NUSNu Skin Enterprises$0.13N/AN/AN/AN/AN/A5/6/2025Q1 2025NATRNature's Sunshine Products$0.1650N/AN/AN/A$109.39 millionN/A4/28/2025Q1 2025MEDMedifast-$0.20N/AN/AN/A$114.85 millionN/A2/18/2025Q4 2024MEDMedifast-$0.16$0.10+$0.26$0.08$114.25 million$119.00 million2/13/2025Q4 2024NUSNu Skin Enterprises$0.24$0.38+$0.14-$0.73$441.10 million$445.55 million2/13/2025Q1 2025VERUVeru-$0.08-$0.07+$0.01-$0.06$2.98 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMEDMedifast$6.6055.18%N/A3,666.67%N/ANATRNature's Sunshine Products$0.403.38%N/A100.00%N/ANUSNu Skin Enterprises$0.244.38%-45.95%N/A N/AVERUVeruN/AN/AN/AN/AN/ALatest VERU, NUS, NATR, and MED DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/13/2025NUSNu Skin Enterprisesquarterly$0.063.2%2/24/20252/24/20253/5/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMEDMedifastN/A3.342.55NATRNature's Sunshine ProductsN/A2.441.51NUSNu Skin Enterprises0.561.821.17VERUVeruN/A4.474.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMEDMedifast95.51%NATRNature's Sunshine Products79.40%NUSNu Skin Enterprises82.84%VERUVeru47.16%Insider OwnershipCompanyInsider OwnershipMEDMedifast2.50%NATRNature's Sunshine Products4.70%NUSNu Skin Enterprises1.70%VERUVeru14.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMEDMedifast87010.94 million10.67 millionOptionableNATRNature's Sunshine Products85018.48 million17.61 millionOptionableNUSNu Skin Enterprises13,40049.72 million48.87 millionOptionableVERUVeru230146.38 million124.57 millionOptionableVERU, NUS, NATR, and MED HeadlinesRecent News About These CompaniesVeru to Present at the 2nd Annual GLP-1-Based Therapeutics SummitApril 16 at 8:30 AM | globenewswire.comVeru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation ConferenceMarch 31, 2025 | globenewswire.comUnusually active option classes on open March 25thMarch 25, 2025 | markets.businessinsider.comVeru Sees Unusually High Options Volume (NASDAQ:VERU)March 18, 2025 | marketbeat.comVeru Inc. Shareholders Approve Equity Plan AmendmentMarch 14, 2025 | tipranks.comHere's Why Veru (VERU) Looks Ripe for Bottom FishingMarch 12, 2025 | msn.comDown -9.23% in 4 Weeks, Here's Why Veru (VERU) Looks Ripe for a TurnaroundMarch 6, 2025 | zacks.comVeru Inc. (NASDAQ:VERU) Director Michael L. Rankowitz Purchases 95,279 SharesFebruary 21, 2025 | insidertrades.comFocus: Next generation weight loss drugs aim to save muscleFebruary 19, 2025 | reuters.comNew weight loss drugs aim to promote muscle growthFebruary 19, 2025 | msn.comVeru Inc. (NASDAQ:VERU) Q1 2025 Earnings Call TranscriptFebruary 14, 2025 | msn.comVeru: Discussions on tariffs are negotiation means to an endFebruary 14, 2025 | msn.comVeru Inc (VERU) Q1 2025 Earnings Call Highlights: Strategic Shifts and Clinical Progress Amid ...February 14, 2025 | finance.yahoo.comVeru targets Phase 3 enobosarm trials following promising Phase 2b results in obesity treatmentFebruary 13, 2025 | msn.comVeru Inc (VERU) Q1 2025 Earnings Call TranscriptFebruary 13, 2025 | seekingalpha.comVeru Inc.: Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program ProgressFebruary 13, 2025 | finanznachrichten.deVeru reports Q1 cont-op EPS (1c) vs. (8c) last yearFebruary 13, 2025 | markets.businessinsider.comEarnings call transcript: Veru Inc Q1 2025 beats EPS forecast, stock dipsFebruary 13, 2025 | msn.comVeru Inc. Reports Positive Phase 2b QUALITY Study Results and Announces New Indication for Sabizabulin in Atherosclerotic Coronary Artery DiseaseFebruary 13, 2025 | quiverquant.comVeru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program ProgressFebruary 13, 2025 | globenewswire.comADAGE CAPITAL PARTNERS GP, L.L.C. Reduces Stake in Veru Inc.February 12, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?Are Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?3 ETFs to Ride the VIX Surge During Market VolatilityBy Nathan Reiff | March 23, 2025View 3 ETFs to Ride the VIX Surge During Market VolatilityIbotta Stock: Why the Buyback Looks Like a Bullish BetBy Gabriel Osorio-Mazilli | March 28, 2025View Ibotta Stock: Why the Buyback Looks Like a Bullish Bet3 Health Insurance Stocks Holding Green in Market TurmoilBy Leo Miller | April 9, 2025View 3 Health Insurance Stocks Holding Green in Market TurmoilVERU, NUS, NATR, and MED Company DescriptionsMedifast NYSE:MED$11.96 -0.19 (-1.56%) As of 03:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.Nature's Sunshine Products NASDAQ:NATR$11.83 -0.05 (-0.42%) As of 03:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.Nu Skin Enterprises NYSE:NUS$5.48 -0.13 (-2.23%) As of 03:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nu Skin Enterprises, Inc., together with its subsidiaries, engages in the development and distribution of various beauty and wellness products worldwide. It offers skin care devices, cosmetics, and other personal care products, including ageLOC LumiSpa and ageLOC LumiSpa iO; and nutricentials skin care products. The company also provides wellness products, such as LifePak nutritional supplements, ageLOC TR90 weight management system, and Beauty Focus Collagen+. In addition, it is involved in the research and product development of skin care products and nutritional supplements. The company sells its products under the Nu Skin, Pharmanex, and ageLOC brands through retail stores, website, digital platforms, and independent direct sellers and marketers, as well as a service center. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.Veru NASDAQ:VERU$0.53 +0.01 (+1.68%) As of 03:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk Tariff-Resistant Abbott Laboratories on Track for New Highs Goldman Sachs Just Revealed What’s Next for Markets United Airlines Is in Reversal—If the Economy Doesn’t Stall Buy the Boeing Dip Even on Tariff and Bans? Spotify Stock Climbs as Its Growth Strategy Diversifies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
